Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Liver Diseases

  Free Subscription


05.02.2024

1 Am J Gastroenterol
1 Anticancer Res
5 BMC Cancer
3 BMC Gastroenterol
2 Cancer
3 Dig Dis Sci
2 Eur Radiol
2 Gastroenterology
1 Hepatology
1 J Gastroenterol Hepatol
26 J Hepatol
1 J Pediatr
2 PLoS One
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Gastroenterol

  1. GE J, Chen IY, Pletcher MJ, Lai JC, et al
    How I Approach It: Prompt Engineering for Generative Artificial Intelligence (GAI) in Gastroenterology and Hepatology.
    Am J Gastroenterol. 2024 Jan 31. doi: 10.14309/ajg.0000000000002689.
    PubMed        


    Anticancer Res

  2. ACS M, Herold Z, Neumann L, Slowik P, et al
    Surgical Treatment and Outcome of Ovarian Cancer Patients With Liver Metastases: Experience of a Tertiary Hepatic and Peritoneal Surface Malignancy Center.
    Anticancer Res. 2024;44:731-741.
    PubMed         Abstract available


    BMC Cancer

  3. TANG C, Zhuang H, Tong H, Yu X, et al
    Identification of FOXP1 as a favorable prognostic biomarker and tumor suppressor in intrahepatic cholangiocarcinoma.
    BMC Cancer. 2024;24:137.
    PubMed         Abstract available

  4. LIVINGSTON PM, Winter N, Ugalde A, Orellana L, et al
    iCare - a self-directed, interactive online program to improve health and wellbeing for people living with upper gastrointestinal or hepato-pancreato-biliary cancers, and their informal carers: the study protocol for a Phase II randomised controlled t
    BMC Cancer. 2024;24:144.
    PubMed         Abstract available

  5. ALI E, Cervenkova L, Palek R, Ambrozkiewicz F, et al
    Prognostic role of macrophages and mast cells in the microenvironment of hepatocellular carcinoma after resection.
    BMC Cancer. 2024;24:142.
    PubMed         Abstract available

  6. WANG S, Wu X, Wu X, Cheng J, et al
    Systematic analysis of the role of LDHs subtype in pan-cancer demonstrates the importance of LDHD in the prognosis of hepatocellular carcinoma patients.
    BMC Cancer. 2024;24:156.
    PubMed         Abstract available

  7. LI F, Wang B, Li H, Kong L, et al
    G6PD and machine learning algorithms as prognostic and diagnostic indicators of liver hepatocellular carcinoma.
    BMC Cancer. 2024;24:157.
    PubMed         Abstract available


    BMC Gastroenterol

  8. FLENSTED-JENSEN M, Oro D, Rorbeck EA, Zhang C, et al
    Dietary intervention reverses molecular markers of hepatocellular senescence in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH.
    BMC Gastroenterol. 2024;24:59.
    PubMed         Abstract available

  9. KUROKAWA S, Kobori T, Yoneda M, Ogawa Y, et al
    Identification of differentially methylated regions associated with both liver fibrosis and hepatocellular carcinoma.
    BMC Gastroenterol. 2024;24:57.
    PubMed         Abstract available

  10. CHEN M, Li Y, Cheng M
    Efficacy and safety of the combination of camrelizumab and apatinib in the treatment of liver cancer: a systematic review and single-arm meta-analysis.
    BMC Gastroenterol. 2024;24:55.
    PubMed         Abstract available


    Cancer

  11. CONNOLLY GK, Harris RD, Shumate C, Rednam SP, et al
    Pediatric cancer incidence among individuals with overgrowth syndromes and overgrowth features: A population-based assessment in seven million children.
    Cancer. 2024;130:467-475.
    PubMed         Abstract available

  12. PORTA C, Negri F, Cosmai L
    Hepatocellular carcinoma, vascular endothelial growth factor receptors-targeting agents, and hypertension: A much more complicated relationship than expected.
    Cancer. 2024 Jan 27. doi: 10.1002/cncr.35218.
    PubMed        


    Dig Dis Sci

  13. BATSAIKHAN B, Dai CY
    Treatment of Hepatocellular Carcinoma in the Elderly: Slash or Burn?
    Dig Dis Sci. 2024 Feb 1. doi: 10.1007/s10620-023-08247.
    PubMed        

  14. KIM JI, Lee J, Choi GH, Lee MW, et al
    Comparison of Surgical Resection and Radiofrequency Ablation in Elderly Patients with Hepatocellular Carcinoma.
    Dig Dis Sci. 2024 Feb 1. doi: 10.1007/s10620-023-08245.
    PubMed         Abstract available

  15. HUANG FD, Zhong YP, Sun GY, Xu QJ, et al
    Fanconi Anemia Complementary Group A (FANCA) Facilitates the Occurrence and Progression of Liver Hepatocellular Carcinoma.
    Dig Dis Sci. 2024 Jan 28. doi: 10.1007/s10620-024-08282.
    PubMed         Abstract available


    Eur Radiol

  16. LIU W, Wei R, Chen J, Li Y, et al
    Prognosis prediction and risk stratification of transarterial chemoembolization or intraarterial chemotherapy for unresectable hepatocellular carcinoma based on machine learning.
    Eur Radiol. 2024 Jan 30. doi: 10.1007/s00330-024-10581.
    PubMed         Abstract available

  17. XU Y, Yang Y, Ouyang J, Zhou Y, et al
    Publisher Correction: Reclassification of therapeutic response of unresectable hepatocellular carcinoma to anti-angiogenic therapy and immunotherapy using alpha RECIST.
    Eur Radiol. 2024 Jan 29. doi: 10.1007/s00330-023-10575.
    PubMed        


    Gastroenterology

  18. WALAYAT S, Pfau P
    2 AM in the Intensive Care Unit: What Could Go Wrong?
    Gastroenterology. 2024;166:e13-e15.
    PubMed        

  19. ALLEN AM, Pose E, Reddy KR, Russo MW, et al
    Nonalcoholic Fatty Liver Disease Gets Renamed as Metabolic Dysfunction-Associated Steatotic Liver Disease: Progress But With Challenges.
    Gastroenterology. 2024;166:229-234.
    PubMed        


    Hepatology


  20. Erratum: Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia.
    Hepatology. 2024 Jan 29. doi: 10.1097/HEP.0000000000000730.
    PubMed        


    J Gastroenterol Hepatol

  21. TOYODA H, Tada T, Uojima H, Nozaki A, et al
    Comparison of six hepatocellular carcinoma prediction models in Japanese patients after sustained virologic response undergoing rigorous surveillance for hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2024 Jan 30. doi: 10.1111/jgh.16494.
    PubMed         Abstract available


    J Hepatol

  22. CAMPION D, Caviglia GP, Alessandria C
    Reply to "The impact of infections on the onset of contrast-associated acute kidney injury in patients with cirrhosis".
    J Hepatol. 2024 Jan 31:S0168-8278(24)00102-8. doi: 10.1016/j.jhep.2024.
    PubMed        

  23. NING Z
    An in-depth exploration of new clinical and prognostic characteristics of decompensated liver cirrhosis patterns.
    J Hepatol. 2024 Jan 31:S0168-8278(24)00104-1. doi: 10.1016/j.jhep.2024.
    PubMed        

  24. SCHNEIDER KM, Schneider CV
    A new era for steatotic liver disease: Evaluating the novel nomenclature in the UK Biobank.
    J Hepatol. 2024;80:e58-e60.
    PubMed        

  25. LI M, Xie W
    Are there all-cause mortality differences between metabolic dysfunction-associated steatotic liver disease subtypes?
    J Hepatol. 2024;80:e53-e54.
    PubMed        

  26. SONG SJ, Lai JC, Wong GL, Wong VW, et al
    Can we use old NAFLD data under the new MASLD definition?
    J Hepatol. 2024;80:e54-e56.
    PubMed        

  27. RATZIU V, Boursier J
    Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD.
    J Hepatol. 2024;80:e51-e52.
    PubMed        

  28. DE A, Bhagat N, Mehta M, Taneja S, et al
    Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with NAFLD.
    J Hepatol. 2024;80:e61-e62.
    PubMed        

  29. SHIPMAN KE
    Sample types and patient preparation required when adopting the new fatty liver disease nomenclature.
    J Hepatol. 2024;80:e60-e61.
    PubMed        

  30. SEMMLER G, Wernly B, Datz C
    What's in a name? New nomenclature for steatotic liver disease - to be or not to be?
    J Hepatol. 2024;80:e56-e58.
    PubMed        

  31. JI H, Cheng S
    Sex differences in prevalence and prognosis of steatotic liver disease phenotypes: Biological sex matters.
    J Hepatol. 2024;80:e68-e69.
    PubMed        

  32. EL-KASSAS M, Alswat K
    Steatotic liver disease as a new nomenclature for NAFLD from the perspectives of the MENA region: One size fits all this time.
    J Hepatol. 2024;80:e66-e68.
    PubMed        

  33. LUO N, Zhang X, Huang J, Chen H, et al
    Prevalence of steatotic liver disease and associated fibrosis in the United States: Results from NHANES 2017-March 2020.
    J Hepatol. 2024;80:e70-e71.
    PubMed        

  34. PERAZZO H, Pacheco AG, Griep RH
    Changing from NAFLD through MAFLD to MASLD: Similar prevalence and risk factors in a large Brazilian cohort.
    J Hepatol. 2024;80:e72-e74.
    PubMed        

  35. SILVA H, King JJ, Thorburn D, Luong TV, et al
    A rare cause of liver fibrosis in an adult patient.
    J Hepatol. 2024;80:e48-e50.
    PubMed        

  36. ESLER WP, Cohen DE
    Pharmacologic inhibition of lipogenesis for the treatment of NAFLD.
    J Hepatol. 2024;80:362-377.
    PubMed         Abstract available

  37. GHALLAB A, Gonzalez D, Strangberg E, Hofmann U, et al
    Inhibition of the Renal Apical Sodium Dependent Bile Acid Transporter Prevents Cholemic Nephropathy in Mice with Obstructive Cholestasis.
    J Hepatol. 2023 Nov 6:S0168-8278(23)05235-2. doi: 10.1016/j.jhep.2023.
    PubMed         Abstract available

  38. ARORA U, Biswas S, Aggarwal S, Duseja A, et al
    MASLD screening and diagnostic algorithms are interchangeable with existing NAFLD literature.
    J Hepatol. 2024;80:e89-e91.
    PubMed        

  39. DI SESSA A, Guarino S, Umano GR, Miraglia Del Giudice E, et al
    MASLD vs. NAFLD: A better definition for children with obesity at higher risk of kidney damage.
    J Hepatol. 2024;80:e87-e89.
    PubMed        

  40. PADILLA J, Osman NM, Bissig-Choisat B, Grimm SL, et al
    Circadian dysfunction induces NAFLD-related human liver cancer in a mouse model.
    J Hepatol. 2024;80:282-292.
    PubMed         Abstract available

  41. HE L, Zheng W, Qiu K, Kong W, et al
    Changing from NAFLD to MASLD: The new definition can more accurately identify individuals at higher risk for diabetes.
    J Hepatol. 2024;80:e85-e87.
    PubMed        

  42. CHOUDHARY NS, Dhampalwar S, Saraf N, Soin AS, et al
    Metabolic dysfunction-associated steatotic liver disease: Where does non-alcoholic fatty liver disease in liver transplant recipients fit in this new definition?
    J Hepatol. 2023 Sep 15:S0168-8278(23)05098-5. doi: 10.1016/j.jhep.2023.
    PubMed        

  43. KIM D, Wijarnpreecha K, Cholankeril G, Ahmed A, et al
    Metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality among adults in the United States.
    J Hepatol. 2024;80:e79-e81.
    PubMed        

  44. JEONG S
    Nutrients associated with metabolic dysfunction-associated steatotic liver disease.
    J Hepatol. 2024;80:e81-e82.
    PubMed        

  45. CHEN L, Tao X, Zeng M, Mi Y, et al
    Clinical and histological features under different nomenclatures of fatty liver disease: NAFLD, MAFLD, MASLD and MetALD.
    J Hepatol. 2024;80:e64-e66.
    PubMed        

  46. SANAL MG
    Is the change from NAFLD to MASLD driven by political correctness?
    J Hepatol. 2024;80:e74-e76.
    PubMed        

  47. HAGSTROM H, Vessby J, Ekstedt M, Shang Y, et al
    99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical.
    J Hepatol. 2024;80:e76-e77.
    PubMed        


    J Pediatr

  48. ORKIN S, Zhao X, Setchell KDR, Carr E, et al
    Food Insecurity and Pediatric Nonalcoholic Fatty Liver Disease Severity.
    J Pediatr. 2024;265:113818.
    PubMed         Abstract available


    PLoS One

  49. OLSON JC, Subramanian RM
    Comparative efficacy of terlipressin and norepinephrine for treatment of hepatorenal syndrome-acute kidney injury: A systematic review and meta-analysis.
    PLoS One. 2024;19:e0296690.
    PubMed         Abstract available

  50. SATO T, Oishi K
    Time-restricted feeding has a limited effect on hepatic lipid accumulation, inflammation and fibrosis in a choline-deficient high-fat diet-induced murine NASH model.
    PLoS One. 2024;19:e0296950.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  51. DAS A, Cheng H, Wang Y, Kinch LN, et al
    The ubiquitin E3 ligase BFAR promotes degradation of PNPLA3.
    Proc Natl Acad Sci U S A. 2024;121:e2312291121.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.